Go Pro

Sutro Biopharma (STRO) Stock Forecast & Price Target

Sutro Biopharma logo
$17.86 -0.49 (-2.65%)
As of 03:42 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sutro Biopharma - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
0
Buy
12

Based on 13 Wall Street analysts who have issued ratings for Sutro Biopharma in the last 12 months, the stock has a consensus rating of "Buy." Out of the 13 analysts, 1 has given a sell rating, 10 have given a buy rating, and 2 have given a strong buy rating for STRO.

Consensus Price Target

$47.30
164.78% Upside
According to the 13 analysts' twelve-month price targets for Sutro Biopharma, the average price target is $47.30. The highest price target for STRO is $60.00, while the lowest price target for STRO is $27.00. The average price target represents a forecasted upside of 164.78% from the current price of $17.86.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for STRO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Sutro Biopharma and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

STRO Analyst Ratings Over Time

TypeCurrent Forecast
9/10/25 to 9/10/26
1 Month Ago
8/11/25 to 8/11/26
3 Months Ago
6/12/25 to 6/12/26
1 Year Ago
9/10/24 to 9/10/25
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
1 Buy rating(s)
Hold
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
4 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$47.30$52.00$49.20$44.67
Forecasted Upside164.78% Upside107.67% Upside70.83% Upside390.63% Upside
Consensus RatingBuyModerate BuyModerate BuyHold

STRO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

STRO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Sutro Biopharma Stock vs. The Competition

TypeSutro BiopharmaHealthcare CompaniesBroader Market
Consensus Rating Score
3.00
2.30
2.53
Consensus RatingBuyHoldModerate Buy
Predicted Upside164.25% Upside952.09% Upside17.22% Upside
News Sentiment Rating
Positive News

See Recent STRO News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/7/2026
Mizuho logo
Mizuho
3 of 5 stars
Salim Syed
Salim Syed
2 of 5 stars
UpgradeStrong-Buy
8/13/2026
Citigroup Inc. logo
Citigroup
4 of 5 stars
 Reiterated RatingMarket Outperform
8/13/2026
Citizens Jmp logo
Citizens Jmp
4 of 5 stars
Reni Benjamin
Reni Benjamin
2 of 5 stars
Lower TargetMarket Outperform$41.00 ➝ $34.00+56.58%
8/13/2026Reiterated RatingOutperform$60.00+181.69%
8/7/2026Set TargetBuy$48.00+98.76%
8/5/2026 Reiterated RatingSell (D-)
6/11/2026Initiated CoverageBuy$50.00+91.64%
5/28/2026Initiated CoverageOverweight$56.00+88.62%
5/15/2026 Set TargetOutperform$38.00 ➝ $43.00+11.92%
5/15/2026Boost TargetBuy$28.00 ➝ $50.00+30.14%
Why major institutions are piling into this digital asset now (Ad)

BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.tc pixel

Get the name, the ticker, and exactly how to buy it
5/1/2026 UpgradeStrong-Buy
3/25/2026Boost TargetBuy$51.00 ➝ $55.00+127.24%
3/24/2026UpgradeEqual WeightOverweight$8.00 ➝ $27.00+26.58%
6/16/2025UpgradeNeutralOverweight$20.00+150.28%
5/19/2025Lower TargetUnderperform$10.00 ➝ $8.00-7.34%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:42 PM ET.


STRO Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Sutro Biopharma is $47.30, with a high forecast of $60.00 and a low forecast of $27.00.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There is currently 1 sell rating, 10 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STRO shares.

According to analysts, Sutro Biopharma's stock has a predicted upside of 164.78% based on their 12-month stock forecasts.

Over the previous 90 days, Sutro Biopharma's stock had 1 upgrade by analysts.

Sutro Biopharma has been rated by research analysts at Citigroup, Citizens Jmp, Mizuho, Stifel Nicolaus, Wedbush, and Weiss Ratings in the past 90 days.

Analysts like Sutro Biopharma more than other "healthcare" companies. The consensus rating for Sutro Biopharma is Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how STRO compares to other companies.


MarketBeat monitors more than a dozen sources for Sutro Biopharma analyst ratings, with the most recent rating issued on 9/7/2026.
From Our Partners